67
Participants
Start Date
January 31, 2016
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
Naltrexone HCl/Bupropion HCl ER
Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
Placebo
Naltrexone HCl/bupropion HCl placebo-matching tablets
Alexander City
Auburn
Birmingham
Huntsville
Campe Verde
Chandler
Cottonwood
Fountain Hills
Mesa
Phoenix
Tucson
Fayetteville
Jonesboro
Little Rock
Arvin
Bakersfield
Chino
Downey
El Cajon
Los Alamitos
Los Angeles
Pomona
Sacramento
Santa Ana
Santa Monica
Denver
New London
Stamford
Trumbull
Waterbury
Wilmington
Boca Raton
Bradenton
Brandon
Brooksville
Coral Springs
Cutler Bay
Daytona Beach
Hialeah
Inverness
Jacksonville Beach
Lake Worth
Largo
Miami Lakes
Orlando
Palm Harbor
Pembroke Pines
Ponte Vedra Beach
Sarasota
Stuart
Atlanta
Duluth
Savannah
Honolulu
Pocatello
Blue Island
Chicago
Evanston
Gurnee
Rock Island
Evansville
Topeka
Louisville
Owensboro
Baton Rouge
Bossier City
Lake Charles
Shreveport
Baltimore
Catonsville
Bay City
Saginaw
Port Gibson
Hazelwood
Great Falls
Las Vegas
Linden
Moorestown
Albuquerque
Endwell
Great Neck
Mineola
New York
Saratoga Springs
Staten Island
Asheville
Cary
Charlotte
Durham
Greenville
Hickory
Morehead City
Raleigh
Rocky Mount
Salisbury
Winston-Salem
Canton
Cincinnati
Cleveland
Columbus
Perrysburg
Sandusky
Willoughby
Altoona
Camp Hill
Doylestown
Lansdale
Pittsburgh
Smithfield
Yardley
Charleston
Moncks Corner
Mt. Pleasant
Simpsonville
Bristol
Jackson
Knoxville
Memphis
Arlington
Dallas
Houston
Katy
Kingwood
Palestine
Plano
San Antonio
Bountiful
Murray
Ogden
Orem
South Ogden
West Jordan
West
Richmond
Roanoke
Virginia Beach
Port Orchard
Charleston
Kenosha
Lead Sponsor
Orexigen Therapeutics, Inc
INDUSTRY